glp 1 agonist and depression Association between GLP-1 receptor use worsening mental illness in people with and anxiety in Sweden: a national cohort study Frontiers | Alleviation of Depression

Along with RAAS inhibitors, these therapies are increasingly regarded as foundational components of DKD management [19,133]

Conflict of interest FB: NovoNordisk and Boehringer-Ingelheim, advisor/consultant/speaker

Each patient's feces, peripheral blood, and intestinal mucosal tissue were tested for miR-1925p and GLP-1 expression

Clinical evidence: key trials and outcomes The kidney-protective potential of SGLT2 inhibitors was first identified in cardiovascular outcome trials, including Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus PatientsRemoving Excess Glucose (EMPA-REG OUTCOME) [36], Canagliflozin Cardiovascular Assessment Study (CANVAS) [37], and Dapagliflozin Effect on Cardiovascular EventsThrombolysis in Myocardial Infarction 58 (DECLARETIMI 58) [38]

Serious side effects are uncommon but possible

However, given the positive CV outcomes, a slight increased heart rate doesnt seem to translate into adverse outcomes